New hope for tough blood cancers: experimental drug MGD024 enters human testing

NCT ID NCT05362773

Recruiting now Disease control Sponsor: MacroGenics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called MGD024 in people with certain blood cancers (like leukemia and lymphoma) that came back or didn't get better with standard treatments. The main goal is to find the safest dose and watch for side effects. About 130 adults will receive the drug for up to a year, and doctors will check how the body responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia aggressive systemic mastocytosis Blastic Plasmacytoid Dendritic Cell Neoplasm CD4+/CD56+ hematodermic neoplasm chronic myelogenous leukemia, BCR-ABL1 positive classic Hodgkin lymphoma hairy cell leukemia Leukemia, B-Cell Leukemia, Myelogenous, Chronic, BCR-ABL Positive Mastocytosis, Systemic myelodysplastic syndrome Myelodysplastic Syndromes precursor B-cell acute lymphoblastic leukemia systemic mastocytosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM CHRONIC MYELOID LEUKEMIA CLASSICAL HODGKIN LYMPHOMA LEUKEMIA ACUTE MYELOID LEUKEMIA, B-CELL LEUKEMIA, HAIRY CELL MASTOCYTOSIS, AGGRESSIVE SYSTEMIC MYELODYSPLASTIC SYNDROMES

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Colorado Blood Cancer Network
RECRUITING

Denver, Colorado, 80218, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

Contact
Duke University Medical Center
COMPLETED

Durham, North Carolina, 27710, United States
START - Midwest
RECRUITING

Grand Rapids, Michigan, 49503, United States
South Austin Medical Center
RECRUITING

Austin, Texas, 78704, United States
University of Maryland, Greenbaum Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21201, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States